Endothelial cells and the IGF system

Journal of Molecular Endocrinology

Volumn 54, Issue 1, 2015, Pages R1-R13

  Bach, Leon A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Angiogenesis; Binding protein; Endothelial cell; Insulin like growth factor; Receptor

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN B; SOMATOMEDIN C;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RETROLENTAL FIBROPLASIA; REVIEW; TISSUE SPECIFICITY; VASCULAR ENDOTHELIUM; ANIMAL; CELL COMMUNICATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA DISEASE; VASCULARIZATION;

ANIMALS; ATHEROSCLEROSIS; CELL COMMUNICATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RETINAL DISEASES;

EID: 84923263916     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0215     Document Type: Review

References (115)

1. Abbas A, Imrie H, Viswambharan H, Sukumar P, Rajwani A, Cubbon RM, Gage M, Smith J, Galloway S, Yuldeshava N et al. 2011 The insulin-like growth factor-1 receptor Is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes 60 2169–2178. (doi:10.2337/db11-0197).
2. Aird WC 2012 Endothelial cell heterogeneity. Cold Spring Harbor Perspectives in Medicine 2 a006429. (doi:10.1101/cshperspect.a006429).
3. Azar WJ, Azar SHX, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA & Russo VC 2011 IGFBP-2 enhances vegf gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152 3332–3342. (doi:10.1210/en.2011-1121).
4. Bach LA, Headey SJ & Norton RS 2005 IGF-binding proteins – the pieces are failing into place. Trends in Endocrinology and Metabolism 16 228–234. (doi:10.1016/j.tem.2005.05.005).
5. Back K, Islam R, Johansson GS, Chisalita SI & Arnqvist HJ 2012 Insulin and IGF1 receptors in human cardiac microvascular endothelial cells: metabolic, mitogenic and anti-inflammatory effects. Journal of Endocrinology 215 89–96. (doi:10.1530/JOE-12-0261).
6. Bailey-Downs LC, Mitschelen M, Sosnowska D, Toth P, Pinto JT, Ballabh P, Valcarcel-Ares MN, Farley J, Koller A, Henthorn JC et al. 2012 Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 67 313–329. (doi:10.1093/gerona/glr164).
7. Bar RS, Clemmons DR, Boes M, Busby WH, Booth BA, Dake BL & Sandra A 1990 Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. Endocrinology 127 1078–1086. (doi:10.1210/endo-127-3-1078).
8. Bastian SEP, Walton PE & Belford DA 1997 Paracellular transport of insulinlike growth factor-I (IGF-I) across human umbilical vein endothelial cell monolayers. Journal of Cellular Physiology 170 290–298. (doi:10.1002/(SICI)1097-4652(199703)170:3!290::AID-JCP10O3.0.CO;2-J).
9. Baxter RC 2014 IGF binding proteins in cancer: mechanistic and clinical insights. Nature Reviews. Cancer 14 329–341. (doi:10.1038/nrc3720).
10. Bid HK, Zhan J, Phelps DA, Kurmasheva RT & Houghton PJ 2012 Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 Is reversed by IGF-2. Molecular Cancer Therapeutics 11 649–659. (doi:10.1158/1535-7163.MCT-11-0575).
11. Boes M, Dake BL & Bar RS 1991 Interactions of cultured endothelial cells with TGF-b, bFGF, PDGF and IGF-I. Life Sciences 48 811–821. (doi:10.1016/0024-3205(91)90097-U).
12. Boes M, Dake BL, Booth BA, Sandra A, Bateman M, Knudtson KL & Bar RS 2003 IGF-I and IGFBP-3 transport in the rat heart. American Journal of Physiology. Endocrinology and Metabolism 284 E237–E239. (doi:10.1152/ajpendo.00336.2002).
13. Brown J, Jones EY & Forbes BE 2009 Keeping IGF-II under control: lessons from the IGF-II–IGF2R crystal structure. Trends in Biochemical Sciences 34 612–619. (doi:10.1016/j.tibs.2009.07.003).
14. Carmeliet P & Jain RK 2000 Angiogenesis in cancer and other diseases. Nature 407 249–257. (doi:10.1038/35025220).
15. Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Calzi SL et al. 2007 IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. PNAS 104 10595–10600. (doi:10.1073/pnas.0702072104).
16. Che WY, Lerner-Marmarosh N, Huang QH, Osawa M, Ohta S, Yoshizumi M, Glassman M, Lee JD, Yan C, Berk BC et al. 2002 Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells – role of Gab1 and MEKK3 in TNF-a-induced c-Jun and NF-k B activation and adhesion molecule expression. Circulation Research 90 1222–1230. (doi:10.1161/01.RES.0000021127.83364.7D).
17. Chisalita SI & Arnqvist HJ 2004 Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. American Journal of Physiology. Endocrinology and Metabolism 286 E896–E901. (doi:10.1152/ajpendo.00327.2003).
18. Cittadini A, Monti MG, Castiello MC, D’Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G et al. 2009 Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelializationina ratmodelof carotid arteryinjury. Journal ofThrombosisand Haemostasis 7 1920–1928. (doi:10.1111/j.1538-7836.2009.03607.x).
19. Clemmons DR 2007 Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews. Drug Discovery 6 821–833. (doi:10.1038/nrd2359).
20. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C & Andreotti F 2004 Insulin-likegrowthfactor-1 asa vascularprotective factor. Circulation 110 2260–2265. (doi:10.1161/01.CIR.0000144309.87183.FB).
21. Conti E, Musumeci MB, De Giusti M, Dito E, Mastromarino V, Autore C & Volpe M 2011 IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clinical Science 120 377–402. (doi:10.1042/CS20100400).
22. Contois LW, Nugent DP, Caron JM, Cretu A, Tweedie E, Akalu A, Liebes L, Friesel R, Rosen C, Vary C et al. 2011 Insulin-like growth factor binding protein-4 (IGFBP-4) differentially inhibits growth factor-induced angiogenesis. Journal of Biological Chemistry 287 1779–1789. (doi:10.1074/jbc.M111.267732).
23. Dahlfors G & Arnqvist HJ 2000 Vascular endothelial growth factor and transforming growth factor-b 1 regulate the expression of insulin-like growth factor-binding protein-3, -4, and -5 in large vessel endothelial cells. Endocrinology 141 2062–2067. (doi:10.1210/endo.141.6.7481).
24. Dean RA, Butler GS, Hamma-Kourbali Y, Delbe J, Brigstock DR, Courty J & Overall CM 2007 Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/ connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Molecular and Cellular Biology 27 8454–8465. (doi:10.1128/MCB.00821-07).
25. Deanfield JE, Halcox JP & Rabelink TJ 2007 Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 1285–1295. (doi:10.1161/CIRCULATIONAHA.106.652859).
26. DeBosch BJ, Deo BK & Kumagai AK 2002 Insulin-like growth factor-1 effects on bovine retinal endothelial cell glucose transport: role of MAP kinase. Journal of Neurochemistry 81 728–734. (doi:10.1046/j.1471-4159.2002.00848.x).
27. Delafontaine P, Song YH & Li YX 2004 Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arteriosclerosis, Thrombosis, and Vascular Biology 24 435–444. (doi:10.1161/01.ATV.0000105902.89459.09).
28. Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA et al. 2010 A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Molecular Cancer Therapeutics 9 1809–1819. (doi:10.1158/1535-7163.MCT-09-1134).
29. Empen K, Lorbeer R, Volzke H, Robinson DM, Friedrich N, Krebs A, Nauck M, Reffelmann T, Ewert R, Felix SB et al. 2010 Association of serum IGF1 with endothelial function: results from the populationbased study of health in Pomerania. European Journal Endocrinology 163 617–623. (doi:10.1530/EJE-10-0563).
30. Ezzat VA, Duncan ER, Wheatcroft SB & Kearney MT 2008 The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes, Obesity & Metabolism 10 198–211. (doi:10.1111/j.1463-1326.2007.00709.x).
31. Firth SM & Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 23 824–854. (doi:10.1210/er.2001-0033).
32. Franklin SL, Ferry RJ & Cohen P 2003 Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. Journal of Clinical Endocrinology and Metabolism 88 900–907. (doi:10.1210/jc.2002-020472).
33. Frasca F, Pandini C, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278–3288.
34. Garrett TPJ, McKern NM, Lou MZ, Frenkel MJ, Bentley JD, Lovrecz GO, Elleman TC, Cosgrove LJ & Ward CW 1998 Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 394 395–399. (doi:10.1038/28668).
35. Gatenby VK, Imrie H & Kearney M 2013 The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium. Pflugers Archiv 465 1065–1074. (doi:10.1007/s00424-013-1218-z).
36. Gealekman O, Gurav K, Chouinard M, Straubhaar J, Thompson M, Malkani S, Hartigan C & Corvera S 2014 Control of adipose tissue expandability in response to high fat diet by the insulin-like growth factor-binding protein-4. Journal of Biological Chemistry 289 18327–18338. (doi:10.1074/jbc.M113.545798).
37. Giannini S, Cresci B, Pala L, Ciucci A, Franchini A, Manuelli C, Fujita-Yamaguchi Y, Cappugi P, Zonefrati R & Rotella CM 2001 IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. Journal of Endocrinology 171 273–284. (doi:10.1677/joe.0.1710273).
38. Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R & Ghigo E 2004 Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB Journal 18 1456–1458. (doi:10.1096/fj.04-1618fje).
39. Granata R, Trovato L, Lupia E, Sala G, Settanni F, Camussi G, Ghidoni R & Ghigo E 2007 Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. FASEB Journal 5 835–845. (doi:10.1111/j.1538-7836.2007.02431.x).
40. Grant M, Jerdan J & Merimee TJ 1987 Insulin-like growth factor-I modulates endothelial cell chemotaxis. Journal of Clinical Endocrinology and Metabolism 65 370–371. (doi:10.1210/jcem-65-2-370).
41. Grillari J, Hohenwarter O, Grabherr RM & Katinger H 2000 Subtractive hybridization of mRNA from early passage and senescent endothelial cells. Experimental Gerontology 35 187–197. (doi:10.1016/S0531-5565(00)00080-2).
42. Han RNN, Post M, Tanswell AK & Lye SJ 2003 Insulin-like growth factor-I receptor-mediated vasculogenesis/angiogenesis in human lung development. American Journal of Respiratory Cell and Molecular Biology 28 159–169. (doi:10.1165/rcmb.4764).
43. Haurigot V, Villacampa P, Ribera A, Llombart C, Bosch A, Nacher V, Ramos D, Ayuso E, Segovia JC, Bueren JA et al. 2009 Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. Journal of Biological Chemistry 284 22961–22969. (doi:10.1074/jbc.M109.014787).
44. Hedbacker K, Birsoy KV, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS & Friedman JM 2010 Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metabolism 11 11–22. (doi:10.1016/j.cmet.2009.11.007).
45. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson- Wikland K, Carlsson B, Niklasson A, Sjodell L et al. 2001 Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. PNAS 98 5804–5808. (doi:10.1073/pnas.101113998).
46. Herr F, Liang OD, Herrero J, Lang U, Preissner KT, Han VKM & Zygmunt M 2003 Possible angiogenic roles of insulin-like growth factor II and its receptors in uterine vascular adaptation to pregnancy. Journal of Clinical Endocrinology and Metabolism 88 4811–4817. (doi:10.1210/jc.2003-030243).
47. Higashi Y, Sukhanov S, Anwar A, Shai SY & Delafontaine P 2010 IGF-1, oxidative stress and atheroprotection. Trends in Endocrinology and Metabolism 21 245–254. (doi:10.1016/j.tem.2009.12.005).
48. Higashi Y, Sukhanov S, Anwar A, Shai SY & Delafontaine P 2012 Aging, atherosclerosis, and IGF-1. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 67 626–639. (doi:10.1093/gerona/gls102).
49. Higashi Y, Pandey A, Goodwin B & Delafontaine P 2013 Insulin-like growth factor-1 regulates glutathione peroxidase expression and activity in vascular endothelial cells: implications for atheroprotective actions of insulin-like growth factor-1. Biochimica et Biophysica Acta 1832 391–399. (doi:10.1016/j.bbadis.2012.12.005).
50. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT & De Bruijn EA 2004 Vascular endothelial growth factor and angiogenesis. Pharmacological Reviews 56 549–580. (doi:10.1124/pr.56.4.3).
51. Huang SS, Ling TY, Tseng WF, Huang YH, Tang FM, Leal SM & Huang JS 2003 Cellular growth inhibition by IGFBP-3 and TGF-b(1) requires LRP-1. FASEB Journal 17 2068–2081. (doi:10.1096/fj.03-0256com).
52. Hynes B, Kumar AH, O’Sullivan J, Klein Buneker C, Leblond AL, Weiss S, Schmeckpeper J, Martin K & Caplice NM 2013 Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. European Heart Journal 34 782–789. (doi:10.1093/eurheartj/ehr435).
53. Imrie H, Abbas A, Viswambharan H, Rajwani A, Cubbon RM, Gage M, Kahn M, Ezzat VA, Duncan ER, Grant PJ et al. 2009 Vascular insulinlike growth factor-I resistance and diet-induced obesity. Endocrinology 150 4575–4582. (doi:10.1210/en.2008-1641).
54. Imrie H, Viswambharan H, Sukumar P, Abbas A, Cubbon RM, Yuldasheva N, Gage M, Smith J, Galloway S, Skromna A et al. 2012 Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. Diabetes 61 2359–2368. (doi:10.2337/db11-1494).
55. Iwatsuki K, Tanaka K, Kaneko T, Kazama R, Okamoto S, Nakayama Y, Ito Y, Satake M, Takahashi S, Miyajima A et al. 2005 Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene 24 1129–1137. (doi:10.1038/sj.onc.1208287).
56. Kielczewski JL, Jarajapu YPR, McFarland EL, Cai J, Afzal A, Calzi SL, Chang KH, Lydic T, Shaw LC, Busik J et al. 2009 Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circulation Research 105 897–U174. (doi:10.1161/CIRCRESAHA.109.199059).
57. Kim KS, Kim M-S, Seu YB, Chung HY, Kim JH & Kim J-R 2007a Regulation of replicative senescence by insulin-like growth factor-binding protein 3 in human umbilical vein endothelial cells. Aging Cell 6 535–545. (doi:10.1111/j.1474-9726.2007.00315.x).
58. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH & Kim JR 2007b Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependentmechanism. Molecular Biology of the Cell 18 4543–4552. (doi:10.1091/mbc.E07-03-0280).
59. Kim JH, Park SW, Yu YS, Kim KW & Kim JH 2012 Hypoxia-induced insulin-like growth factor II contributes to retinal vascularization in ocular development. Biochimie 94 734–740. (doi:10.1016/j.biochi.2011.11.003).
60. Kim KS, Kim JE, Choi KJ, Bae S & Kim DH 2014 Characterization of DNA damage-induced cellular senescence by ionizing radiation in endothelial cells. International Journal of Radiation Biology 90 71–80. (doi:10.3109/09553002.2014.859763).
61. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M & Kahn CR 2003 Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. Journal of Clinical Investigation 111 1835–1842. (doi:10.1172/JCI200317455).
62. Lee OH, Bae SK, Bae MH, Lee YM, Moon EJ, Cha HJ, Kwon YG & Kim KW 2000 Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models. British Journal of Cancer 82 385–391. (doi:10.1054/bjoc.1999.1022).
63. Leksa V, Godar S, Schiller HB, Fuertbauer E, Muhammad A, Slezakova K, Horejsi V, Steinlein P, Weidle UH, Binder BR et al. 2005 TGF-b-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and miniplasminogen. Journal of Cell Science 118 4577–4586. (doi:10.1242/jcs.02587).
64. Li GL, Barrett EJ, Wang H, Chai WD & Liu ZQ 2005 Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 146 4690–4696. (doi:10.1210/en.2005-0505).
65. Liu WL, Liu YQ & Lowe WL 2001 The role of phosphatidylinositol 3-kinase and the mitogen-activated protein kinases in insulin-like growth factor-Imediated effects in vascular endothelial cells. Endocrinology 142 1710–1719. (doi:10.1210/endo.142.5.8136).
66. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S & Cohen P 2007 Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26 1811–1819. (doi:10.1038/sj.onc.1209977).
67. Liu SJ, Zhong Y, You XY, Liu WH, Li AQ & Liu SM 2014 Insulin-like growth factor 1 opposes the effects of C-reactive protein on endothelial cell activation. Molecular and Cellular Biochemistry 385 199–205. (doi:10.1007/s11010-013-1828-y).
68. Lofqvist C, Chen J, Connor KM, Smith ACH, Aderman CM, Liu N, Pintar JE, Ludwig T, Hellstrom A & Smith LEH 2007 IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. PNAS 104 10589–10594. (doi:10.1073/pnas.0702031104).
69. Maeng YS, Choi HJ, Kwon JY, Park YW, Choi KS, Min JK, Kim YH, Suh PG, Kang KS, Won MH et al. 2009 Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCb2 axis. Blood 113 233–243. (doi:10.1182/blood-2008-06-162891).
70. Messmer-Blust A, An X & Li J 2009 Hypoxia-regulated angiogenic inhibitors. Trends in Cardiovascular Medicine 19 252–256. (doi:10.1016/j.tcm.2010.02.006).
71. Moreno MJ, Ball M, Andrade MF, McDermid A & Stanimirovic DB 2006 Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel antiangiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia 53 845–857. (doi:10.1002/glia.20345).
72. Moser DR, Lowe WL Jr, Dake BL, Booth BA, Boes M, Clemmons DR & Bar RS 1992 Endothelial cells express insulin-like growth factor-binding proteins 2 to 6. Molecular Endocrinology 6 1805–1814. (doi:10.1210/mend.6.11.1282670).
73. Muck C, Micutkova L, Zwerschke W & Jansen-Durr P 2008 Role of insulin-like growth factor binding protein-3 in human umbilical vein endothelial cell senescence. Rejuvenation Research 11 449–453. (doi:10.1089/rej.2007.0628).
74. Nakao-Hayashi J, Hideki I, Kanayasu T, Morita I & Murota S 1992 Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Arteriosclerosis 92 141–149. (doi:10.1016/0021-9150(92)90273-J).
75. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK et al. 2006 Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clinical Cancer Research 12 653–661. (doi:10.1158/1078-0432.CCR-05-1725).
76. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD & Virmani R 2012 The importance of the endothelium inatherothrombosis andcoronary stenting. Nature Reviews. Cardiology 9 439–453. (doi:10.1038/nrcardio.2012.64).
77. Pan Y, Liang H, Liu H, Li D, Chen X, Li L, Zhang CY & Zen K 2014 Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. Journal of Immunology 192 437–446. (doi:10.4049/jimmunol.1301790).
78. Panganiban RA & Day RM 2013 Inhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescence. PLoS ONE 8 e78589. (doi:10.1371/journal.pone.0078589).
79. Perticone F, Sciacqua A, Perticone M, Laino I, Miceli S, Care I, Galiano Leone G, Andreozzi F, Maio R & Sesti G 2008 Low-plasma insulin-like growth factor-I levels are associated with impaired endotheliumdependent vasodilatation in a cohort of untreated, hypertensive Caucasian subjects. Journal of Clinical Endocrinology and Metabolism 93 2806–2810. (doi:10.1210/jc.2008-0646).
80. Png KJ, Halberg N, Yoshida M & Tavazoie SF 2012 AmicroRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481 190–194. (doi:10.1038/nature10661).
81. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915–928. (doi:10.1038/nrc2536).
82. Potente M, Gerhardt H & Carmeliet P 2011 Basic and therapeutic aspects of angiogenesis. Cell 146 873–887. (doi:10.1016/j.cell.2011.08.039).
83. Rho SB, Dong SM, Kang S, Seo S-S, Yoo CW, Lee DO, Woo JS & Park S-Y 2008 Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis 29 2106–2111. (doi:10.1093/carcin/bgn206).
84. Rombouts C, Aerts A, Quintens R, Baselet B, El-Saghire H, Harms-Ringdahl M, Haghdoost S, Janssen A, Michaux A, Yentrapalli R et al. 2014 Transcriptomic profiling suggests a role for IGFBP5 in premature senescence of endothelial cells after chronic low dose rate irradiation. International Journal of Radiation Biology 90 560–574. (doi:10.3109/09553002.2014.905724).
85. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C et al. 2004 Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. Journal of Clinical Investigation 113 1149–1157. (doi:10.1172/JCI19478).
86. Semenza GL 2012 Hypoxia-inducible factors in physiology and medicine. Cell 148 399–408. (doi:10.1016/j.cell.2012.01.021).
87. Shelton DN, Chang E, Whittier PS, Choi D & Funk WD 1999 Microarray analysis of replicative senescence. Current Biology 9 939–945. (doi:10.1016/S0960-9822(99)80420-5).
88. Slomiany MG & Rosenzweig SA 2006 Hypoxia-inducible factor-1- dependent and -independent regulation of insulin-like growth factor-1- stimulated vascular endothelial growth factor secretion. Journal of Pharmacology and Experimental Therapeutics 318 666–675. (doi:10.1124/jpet.106.104158).
89. Smith LEH, Shen W, Perruzzi C, Soker S, Kinose F, Xu XH, Robinson G, Driver S, Bischoff J, Zhang B et al. 1999 Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nature Medicine 5 1390–1395. (doi:10.1038/70963).
90. Spoerri PE, Ellis EA, Tarnuzzer RW & Grant MB 1998 Insulin-like growth factor – receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non diabetic origin. Growth Hormone & IGF Research 8 125–132. (doi:10.1016/S1096-6374(98)80102-0).
91. Stearns M, Tran J, Francis MK, Zhang H & Sell C 2005 Activated ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Research 65 2085–2088. (doi:10.1158/0008-5472.CAN-04-4100).
92. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J & Delafontaine P 2007 IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 27 2684–2690. (doi:10.1161/ATVBAHA.107.156257).
93. Sumpio BE, Riley JT & Dardik A 2002 Cells in focus: endothelial cell. International Journal of Biochemistry & Cell Biology 34 1508–1512. (doi:10.1016/S1357-2725(02)00075-4).
94. Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA et al. 2007a Age-dependent impairment of endothelial progenitor cells is corrected by growthhormone- mediated increase of insulin-like growth-factor-1. Circulation Research 100 434–443. (doi:10.1161/01.RES.0000257912.78915.af).
95. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J & Stichtenoth DO 2007b Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 92 4172–4179. (doi:10.1210/jc.2007-0922).
96. Tivesten A, Bollano E, Andersson I, Fitzgerald S, Caidahl K, Sjogren K, Skott O, Liu JL, Mobini R, Isaksson OGP et al. 2002 Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in mice. Endocrinology 143 4235–4242. (doi:10.1210/en.2002-220524).
97. Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ & Han VKM 1998 Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. Journal of Endocrinology 157 13–24. (doi:10.1677/joe.0.1570013).
98. Valastyan S & Weinberg RA 2011 Tumor metastasis: molecular insights and evolving paradigms. Cell 147 275–292. (doi:10.1016/j.cell.2011.09.024).
99. Volpert O, Jackson D, Bouck N & Linzer DIH 1996 The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferininduced angiogenesis. Endocrinology 137 3871–3876. (doi:10.1210/endo.137.9.8756559).
100. Wang W, Kumar P, Wang WZ, Epstein J, Helman L, Moore JV & Kumar S 1998 Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Research 58 4426–4433.
101. Wang H, Liu Z, Li G & Barrett EJ 2006 The vascular endothelial cell mediates insulin transport into skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism 291 E323–E332. (doi:10.1152/ajpendo.00047.2006).
102. Wang X, Huang W, Liu G, Cai W, Millard RW, Wang Y, Chang J, Peng T & Fan GC 2014 Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer ofmiR-320 into endothelial cells. Journal of Molecular and Cellular Cardiology 74 139–150. (doi:10.1016/j.yjmcc.2014.05.001).
103. Warren RS, Yuan H, Matli MR, Ferrara N & Donner DB 1996 Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. Journal of Biological Chemistry 271 29483–29488. (doi:10.1074/jbc.271.46.29483).
104. Wheatcroft SB & Kearney MT 2009 IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends in Endocrinology and Metabolism 20 153–162. (doi:10.1016/j.tem.2009.01.002).
105. Wilkinson-Berka JL, Wraight C & Werther G 2006 The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Current Medicinal Chemistry 13 3307–3317. (doi:10.2174/092986706778773086).
106. Wood AW, Schlueter PJ & Duan C 2005 Targeted knockdown of insulin-like growth factor binding protein-2 disrupts cardiovascular development in zebrafish embryos. Molecular Endocrinology 19 1024–1034. (doi:10.1210/me.2004-0392).
107. Yang YW-H, Piolo P, Fiorelli G, Brandi ML & Rechler MM 1993 Cyclic adenosine monophosphate stimulates insulin-like growth factor binding protein-4 and its messenger ribonucleic acid in a clonal endothelial cell line. Endocrinology 133 343–351. (doi:10.1210/endo.133.1.7686482).
108. Yang AL, Yeh CK, Su CT, Lo CW, Lin KL & Lee SD 2010 Aerobic exercise acutely improves insulin- and insulin-like growth factor-1-mediated vasorelaxation in hypertensive rats. Experimental Physiology 95 622–629. (doi:10.1113/expphysiol.2009.050146).
109. Yuldasheva NY, Rashid ST, Haywood NJ, Cordell P, Mughal R, Viswambharan H, Imrie H, Sukumar P, Cubbon RM, Aziz A et al. 2014 Haploinsufficiency of the insulin-like growth factor-1 receptor enhances endothelial repair and favorably modifies angiogenic progenitor cell phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology 34 2051–2058. (doi:10.1161/atvbaha.114.304121).
110. Zeng G & Quon MJ 1996 Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. Journal of Clinical Investigation 98 894–898. (doi:10.1172/JCI118871).
111. Zhang C, Lu L, Li Y, Wang X, Zhou J, Liu Y, Fu P, Gallicchio MA, Bach LA & Duan C 2012 IGF binding protein-6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis. International Journal of Cancer 130 2003–2012. (doi:10.1002/ijc.26201).
112. Zhang Q, Soderland C & Steinle JJ 2013a Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor. Apoptosis 18 361–368. (doi:10.1007/s10495-012-0793-3).
113. Zhang Q, Jiang Y, Toutounchian JJ, Soderland C, Yates CR & Steinle JJ 2013b Insulin-like growth factor binding protein-3 inhibits monocyte adhesion to retinal endothelial cells in high glucose conditions. Molecular Vision 19 796–803.
114. Zhang Q, Jiang Y, Miller MJ, Peng B, Liu L, Soderland C, Tang J, Kern TS, Pintar J & Steinle JJ 2013c IGFBP-3 and TNF-a regulate retinal endothelial cell apoptosis. Investigative Ophthalmology & Visual Science 54 5376–5384. (doi:10.1167/iovs.13-12497).
115. Zhang Q, Soderland D & Steinle JJ 2014 TNFa Inhibits iGFBP-3 through activation of p38a and casein kinase 2 in human retinal endothelial cells. PLoS ONE 9 e103578. (doi:10.1371/journal.pone.0103578).